HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Insect repellent efficacy

This article was originally published in The Rose Sheet

Executive Summary

Deet-containing insect repellents protect against mosquito bites for a longer duration than botanical and "alternative" repellants currently available, Mark Fradin, MD, says in research published in July 4 New England Medical Journal. S.C. Johnson's Off! Deep Woods, formulated with 23.8% Deet, provided an average of 301.5 minutes of protection, while OFF! Skintastic for Kids, with 4.75% Deet protected for 88 minutes, study shows. By comparison, Avon's Skin-So-Soft Bug Guard Plus, made with 7.5% IR3535, protected for an average of 22.9 minutes. Other Skin-So-Soft formulations protected for even shorter durations of time, according to the findings. Study compared six Deet-containing repellents with 10 alternative formulations. Avon refutes results in July 3 statement, maintaining lab tests used in study are not as appropriate as field tests for establishing efficacy of repellents...

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel